Forte Biosciences Inc FBRX

$76.99 +0.02 (0.03%)

Valuation

Market cap
1,634,421,000
Revenue TTM
$0
Net income TTM
$-69,380,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,400,100
Avg volume
1,625,418
Day's range
$76.96 – $77.00
Shares out
21,229,000
Stochastic %K
94%
Beta
2.62
Analysts
Hold
Price target
$77.00

Price

Company profile

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc...

Show more

Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary of argenx SE.

Industry
Biotechnology
Sector
Healthcare
Phone
310 618 6994
Website
https://www.fortebiorx.com
Address
3060 Pegasus Park Drive, Building 6, Dallas, United States

Latest news

Stocktwits

YouVSYou Sep 1, 4:18 AM
$GPRO $ASST $FBRX $FCEL $VVOS Always ready. YVY
1 replies
Merlintrader Aug 28, 1:42 PM
$FBRX argenx completed the $77.00 per share cash acquisition of Forte Biosciences on August 27. The offer expired August 26 with 19,894,879 shares tendered, about 87.13% counting what argenx already held, and the merger followed the same day under Section 251(h) with no shareholder vote. Nasdaq filed the Form 25 and FBRX no longer trades. Full stock hub, free to read, every figure checked on the closing filings. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/forte-biosciences-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=forte-biosciences-stock-hub
0 replies
porky1963 Aug 28, 5:42 AM
$FBRX nice retutn with $LEXX so getting into $RARE.
0 replies
Merlintrader Aug 27, 10:58 AM
$FBRX is halted. The argenx tender offer was set to expire one minute after 11:59 pm Eastern on August 26, Nasdaq halted the stock at the end of that day's after-hours session and has set the listing suspension for August 28 if the merger closes as planned. Merger consideration is 77.00 dollars per share. No completion release and no closing filing had appeared this morning. https://www.merlintrader.com/forte-biosciences-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=forte-biosciences-stock-hub
0 replies
Mergerbrief Aug 26, 11:46 AM
$FBRX / $ARGX – Tender Offer Expires
0 replies
MX1074 Aug 24, 5:14 PM
$FBRX Does anyone know if the purchase operation by ARGENX was successful? Thanks in advance
0 replies
TwongStocks Aug 21, 7:33 PM
$FBRX Equity Corporate Actions Alert #2026 - 597 Information Regarding the Tender Offer of Forte Biosciences, Inc. (FBRX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-597 The tender offer by argenx (ARGX) to acquire all of the outstanding common stock of Forte Biosciences, Inc. (FBRX) is scheduled to expire one minute after 11:59 p.m. ET, on August 26, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on August 27, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on August 26, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (August 27) and will be suspended effective August 28, 2026. Merger consideration is $77 per share.
0 replies
porky1963 Aug 20, 8:02 AM
$FBRX chinese companys are on the lookout to buy european and american BIO+IA companys soon.picking what they go for is the QUESTION.
0 replies